CSL: Result 2015

CSL's growth was slow in 2015, but management has high hopes for its new influenza business.

Blood products maker CSL has reported a decent full year result, with revenue increasing 2% to US$5.5bn compared to a year earlier, or 7% after removing the effect of currency fluctuations. At constant currency and excluding one-off acquisition costs for its new influenza unit (see below), net profit increased 10% to US$1.4bn while earnings per share increased 13% to $2.91 due to the ongoing share buyback program.


{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles